Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma

BACKGROUND: Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) offers limited benefits, but survival outcomes vary. Reliable predictive response biomarkers to guide patient management are lacking. METHODS: Patient performance status, tumour burden (determined by the presence or absence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayimu, Alimu, Di Lisio, Lorena, Anand, Shubha, Roca-Carreras, Isart, Qian, Wendi, Al-Mohammad, Abdulrahman, Basu, Bristi, Valle, Juan W., Jodrell, Duncan, Demiris, Nikos, Corrie, Pippa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133256/
https://www.ncbi.nlm.nih.gov/pubmed/36813867
http://dx.doi.org/10.1038/s41416-023-02170-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133256/
https://www.ncbi.nlm.nih.gov/pubmed/36813867
http://dx.doi.org/10.1038/s41416-023-02170-9

Ejemplares similares